Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02945020 · ClinicalTrials.gov registry record · Phase 1
A Pharmacokinetic Interaction Study Between Odalasvir, Given as a Single Agent or in Combination With Simeprevir, and Dabigatran Etexilate Mesylate in Healthy Participants
A Phase 1 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT02945020 is a Phase 1 study that has completed, run by Janssen Research & Development. The registered enrollment target is 15 participants.
The verdict
NCT02945020, a Phase 1 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effect of steady-state concentrations of odalasvir (ODV), as a single agent or in combination with simeprevir (SMV), on the single-dose pharmacokinetics of dabigatran etexilate in healthy participants.
Interventions
- DRUG Dabigatran etexilate mesylate
- DRUG Odalasvir (ODV)
- DRUG Simeprevir (SMV)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2016-11-10 |
| Est. Completion | 2017-01-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02945020
The ClinicalTrials.gov registry entry for NCT02945020 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Dabigatran etexilate mesylate is the first listed.
NCT02945020 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02945020 about?
NCT02945020 is a clinical study titled "A Pharmacokinetic Interaction Study Between Odalasvir, Given as a Single Agent or in Combination With Simeprevir, and Dabigatran Etexilate Mesylate in Healthy Participants". The purpose of this study is to evaluate the effect of steady-state concentrations of odalasvir (ODV), as a single agent or in combination with simeprevir (SMV), on the single-dose pharmacokinetics of dabigatran etexilate in healthy participants.
What is the current status of trial NCT02945020?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2016-11-10. Estimated completion is 2017-01-20.
What interventions are being tested in trial NCT02945020?
The interventions under investigation include: Dabigatran etexilate mesylate (DRUG), Odalasvir (ODV) (DRUG), Simeprevir (SMV) (DRUG).
Who is sponsoring clinical trial NCT02945020?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.